Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 165

Experts have equipped biotech workhorse bacteria with feedback control mechanism to balance growth with making protein products.

Medicines like insulin and interferon are manufactured using genetically engineered bacteria, such as E. coli. E. coli grow quickly and can be given DNA that instructs them to make proteins used in medicines and other materials.

However, the extra burden of producing new proteins hampers bacterial growth, which slows production. Solving this problem is an area of great interest for biotechnology and synthetic biology.

Read more

Wilmington, DE, April 19, 2018 — Scientists at Christiana Care Health System’s Gene Editing Institute have developed a potentially breakthrough CRISPR gene-editing tool. It could allow researchers to take fragments of DNA extracted from human cells, put them into a test tube, and quickly and precisely engineer multiple changes to the genetic code, according to a new study published today in the CRISPR Journal.

Investigators at the Gene Editing Institute, which is part of the Helen F. Graham Cancer Center & Research Institute at Christiana Care, said their new “cell-free” CRISPR technology is the first CRISPR tool capable of making multiple edits to DNA samples “in vitro,” which means in a test tube or petri dish. The advance could have immediate value as a diagnostic tool, replicating the exact genetic mutations found in the tumors of individual cancer patients. Mutations that cause cancer to spread can differ from patient to patient, and being able to quickly identify the correct mutation affecting an individual patient can allow clinicians to implement a more targeted treatment strategy.

“With this new advance, we should be able to work with laboratory cultures and accomplish gene edits in less than a day, significantly reducing the time required for diagnostics compared to other CRISPR tools, and with much greater precision,” said Eric Kmiec, Ph.D., director of the Gene Editing Institute and principal author of the study. “This is particularly important for diagnostics linked to cancer care where time is critical.”

Read more

In a big win for the biotech industry, the US Department of Agriculture says once and for all it won’t regulate plants whose genomes have been altered using gene-editing technology.

Why it’s a field day: The decision means that we could see a boom in newfangled plants from firms like Monsanto, universities, and startups like Calyxt, whose oil-altered soybeans featured in our cover story late last year.

Here’s the logic: The USDA says gene editing is just a (much) faster form of breeding. So long as a genetic alteration could have been bred into a plant, it won’t be regulated. That includes changes that create immunity to disease or natural resistance to crop chemicals, as well as edits to make seeds bigger and heavier. It doesn’t include transgenic plants (those with a gene from a distant species)—those will still be regulated.

Read more

  • Basic income will be widespread by the 2030s, according to Google futurist and director of engineering Ray Kurzweil.
  • Kurzweil is known for making seemingly wild predictions. In 2016, he predicted that by 2029, medical technology will add an extra year to human life expectancies on an annual basis.
  • ” We’re going to have more and more powerful technology to keep our physical bodies going. We’ll think, ‘Wow, back in 2018, people only had one body, and they couldn’t back up their mind file,’” he said onstage at TED.

As it becomes apparent that artificial intelligence will replace ever-more jobs in the coming years, a growing number of politicians, nonprofits, and Silicon Valley entrepreneurs have started thinking about how we’ll cope with a world in which not everyone can — or needs to — work.

Basic income experiments, in which people are given a regular salary just to live, no strings attached, are popping up all over Europe, Africa, and North America.

Read more